1 FDA’s Proposed Revised 21 CFR 207 Rule and Electronic Drug Registration and Listing Systems (e-DRLS) John W. Gardner, MD, DrPH Director, DCRMS / OC /

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Structured Product Labeling Overview
U.S. Food and Drug Administration
Process for Submission and Drug Listing Rx Human Drugs* Posting to Daily Med –SPL r3 - occurs via the FDA application process utilizing ELIPS –SPL r4 -
1 DIA Webinar SPL R4 : Electronic Drug Establishment Registration and Drug Listing September 9, 2008 LCDR Vada Perkins, USPHS FDA/CBER/OD.
Assures that feed… –has the identity and strength, which it purports –meets the quality, purity, and safety requirements, which it is represented to possess.
ILISA B.G. BERNSTEIN, PHARM.D., J.D. U.S. Food and Drug Administration
GMP Document and Record Retention
Food Safety Modernization Act (FSMA) Key Themes/Concepts Jeannie Perron, JD, DVM Covington & Burling LLP.
510k Submission Overview Myraqa, Inc. August 22, 2012.
October/November 2007 Federal Deficit Reduction Act (DRA) October/November 2007.
“Paperless Labeling Rule” Proposed Rule First Look January 2015.
History of FDA and Related Regulatory Agencies
1 APMA SPL: Electronic Drug Establishment Registration and Drug Listing/Content of Labeling October 10, 2008 CDR Vada Perkins, USPHS FDA/CBER/OD.
Introduction to Regulation
Pharmacology Application in Athletic Training Michelle Odai, MS, LAT, ATC, CSCS Florida International University.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
1 The FDA and Animal Drug Compounding Neal Bataller, DVM FDA/Center for Veterinary Medicine AAVPT 14 th Biennial Symposium, May 16-17, 2005, Rockville,
Chapter 6 Dispensing Medications in the Community Pharmacy
 Overview The Drug Compendia  Review Drug Compendia Processes  Benefits of SPL.
April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.
FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.
Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,
Overview of the New Content and Format Requirements for Prescription Drug Labeling.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
Establishment Registration and Device Listing Rod Perez, M.S.E. Consumer Safety Officer Division of Small Manufacturers, International and Consumer Assistance.
Labeling and Program Delivery Division USDA, FSIS, OPPD
FDA Bar Code Rule Richard A. Nickel, M.S., R.Ph. Mallinckrodt Inc. St. Louis, MO.
Downstream Use of Structured Product Labeling Thomas R. Bizzaro, R.Ph. Vice President, Health policy and Industry Relations SPL/DailyMed Jamboree Workshop.
Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Richard Siegersma General Manager Thorpe-Bowker Australian ISBN agency since 1997.
Chapter One. Drug Standards- rules set to assure consumers that they get what they pay for; all preparations called by the same drug name.
PwC 21 CFR Part 11 – A Risk Management Perspective Patrick D. Roche 07 March 2003, Washington D.C.
The Proposed Changes to NDC System Legacy NDC Numbers and Compliance December 11, 2006 Dr. Thomas F. Willer Director Global Regulatory Affairs.
Final Rule for Preventive Controls for Human Food September 16, THE FUTURE IS NOW 1.
Overview of FDA's Regulatory Framework for PET Drugs
Compounding Kenneth Schell Pharm. D President, CA State Board of Pharmacy.
Business Management and Education Institute (BMEI) FDA IMPORT INFORMATION.
Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.
FDA Regulatory and Compliance Symposium
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Final Rule for Preventive Controls for Animal Food 1 THE FUTURE IS NOW.
Chapter 6 Dispensing Medications in the Community Pharmacy.
Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.
Federal Medication Terminologies (FMT) Enabling Health IT Interoperability.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Technology, Information Systems and Reporting in Pharmacy Benefit Management Presentation Developed for the Academy of Managed Care Pharmacy Updated: February.
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
© 2016 Chapter 6 Data Management Health Information Management Technology: An Applied Approach.
Dailymed/RxNorm Jamboree Leyla Rahjou-Esfandiary September 2016
Common SPL Errors Experienced by FDA DRLS
Final Rule for Preventive Controls for Human Food
Drugs and Prescription Records
Drugs and Prescription Records
The Information Professional’s Role in Product Safety
American Society for Quality Region 5 Quality Conference
SPL Implementation Working Group Leyla Rahjou-Esfandiary October 2016
Learning Objectives Enumerate typical duties of pharmacy technicians with regard to dispensing of over-the-counter and prescription drugs. Explain the.
Labeling and Electronic Initiatives
PRESCRIPTIONS Chap. 5.
Lori Tortora Foreign Agriculture Service
FDA Resources and Meetings
Compounded Drugs and Lack of Premarket FDA-Approval
Final Rule on Foreign Supplier Verification Programs
Presentation transcript:

1 FDA’s Proposed Revised 21 CFR 207 Rule and Electronic Drug Registration and Listing Systems (e-DRLS) John W. Gardner, MD, DrPH Director, DCRMS / OC / CDER

2 Proposed Revised 21 CFR 207 Electronic submission of Registration and Listing information –Establishment Registration through DFRM/FURLS –Drug Product Listing information through eLIST Electronic submission of Content of Labeling FDA issues the complete NDC number –FDA posts valid NDC numbers in NDC Directory & DailyMed NDC number printed on product labels –Most recent firm’s NDC number (traceable back to origin) Firms must re-certify their Listing information every 6 months

3 What is DRLS? Establishment Registration and Drug Listing laws were enacted to help protect the public from adulterated and misbranded drugs Drug establishments must Register annually with FDA, providing names, addresses, contact information, and manufacturing roles Firms must List with FDA all drug products being marketed in the United States, providing names, ingredients, manufacturer, etc.

4 DRLS Use: Drug Regulation and Enforcement Repository of NDC numbers; Registration provides labeler component of NDC Registration provides locations and contact information for drug establishments and identifies sites for inspection Listing provides manufacturing information and ingredients for marketed drug products Helps identify violative drug products Assists with control of drug imports

5 DRLS Use: Drug Safety Supports SPL/DailyMed Initiative and provides linkage of drug product identification with drug product labeling, FDA approval, and manufacturer and marketer information Helps support Counter-Terrorism efforts Helps support BSE control programs Supports FDA safety-related databases Identifies products in drug shortages and product ingredients for recalls Provides repository of drug product labeling

6 DRLS Use: Drug Billing and Reimbursement CMS uses DRLS information to determine drug eligibility for Medicare and Medicaid reimbursement and rebate programs The NDC Directory is widely used by public and private organizations to identify drug products for third-party reimbursement and for additional data analyses Nearly all drug/pharmacy billing systems use the NDC numbers archived in DRLS and published in the NDC Directory

7 Database History Started as paper system in 1970s Current Oracle system created 1991 Electronic Registration and Listing Systems currently in development DFRM/FURLS — Online Drug Facility Registration eLIST — Electronic Drug Product Listing

8 DRLS Database* Total Active Facilities Human Drug Domestic Manufacturing Sites – 9,417 Human Drug Foreign Sites – 6,068 Domestic Private Label Distributor Sites – 8,586 Veterinary Drug Sites – 3,441 Total Active Products Total Rx Drug Products – 68,219 Total Bulk Ingredients – 17,446 10,337 registration forms and 30,571 listing forms entered in 2005 * as of 8/4/2006

9 Registration Database Information Firm information: Name Labeler code Contacts & Compliance address (usually HQ) US Agent and Importers (if foreign) Manufacturing site information: FEI number (FDA Establishment Identifier) Site address and function Mailing address Parent Company Other firms operating at site Registration History Country code (based on Site address) Human drug site, Vet drug site, or both Types of Operations performed

10 Drug Listing Database Information Product information Listing Status Full NDC (National Drug Code [Labeler-Product-Package] ) Trade name and generic name Rx/OTC; DEA class Formulation – includes active and inactive ingredients and active ingredient strengths Dosage form and route of administration Packaging information: size, type, quantity Firm’s function Manufacturer Repacker Labeler Private Label Distributor

11 Future  e-DRLS Plans for e-DRLS to provide electronic submission and online annual/semi-annual verification/updating of registration/listing This will greatly improve data accuracy, minimize data input requirements, and allow more focus on safety and regulatory issues Plans for e-DRLS to implement new features of registration and listing, including partially- automated validation of listings

12 Drug Establishment Registration Electronic registration is coming! The Drug Facility Registration Module (DFRM) is implemented in the FDA Uniform Registration & Listing System (FURLS) FURLS will soon provide access for industry Firms logging-in to FURLS will utilize DFRM to enter firm and importer information All paper forms will eventually be eliminated Annual updating will be greatly simplified Other FDA systems will eventually utilize FURLS as the master inventory of drug establishments & their official contact and importer information

13 DFRM Update Registration [Hypothetical Firm]

14 DFRM Update Registration [Hypothetical Firm]

15 DFRM Update Registration [Hypothetical Firm]

16 DFRM Update Registration [Hypothetical Firm]

17 DFRM Update Registration [Hypothetical Firm]

18 DFRM Update Registration [Hypothetical Firm]

19 DFRM Update Registration [Hypothetical Firm]

20 Structured Product Labeling The Electronic Labeling Rule provided a platform for XML electronic Structured Product Label (SPL) – content of labeling SPL allows electronic edit, search, review, and archiving of drug labeling – [prescriber package insert] In October 2005 industry started providing SPL for application human prescription drugs After FDA review, these are posted for public access/download at NLM’s DailyMed web site This will eventually integrate with electronic prescribing & public drug information access

21 Electronic Listing – eLIST FDA is developing an electronic listing system (eLIST) that will eventually allow industry to provide listing information via SPL submission SPL includes coded data elements for most of the required listing information eLIST will extract coded data from the SPL for Listing; industry will log-in through FURLS to provide some information not in the SPL eLIST will validate listing information, including NDC number, drug approval, and label approval prior to public posting in DailyMed and the NDC Directory

22 Efficiencies with eLIST The planned eLIST is designed to greatly facilitate drug listing for industry and improve accuracy and completeness of data Eliminate duplicative and redundant data entry Ensure that listing data matches labeling (SPL) eLIST will automate validation of drug approval status and of compliance with certain OTC Monograph requirements eLIST will provide electronic archiving for drug product labels eLIST will provide accurate linkage with NDC Directory and FDA’s drug information systems

23 Driver SourceInformationData FDA System FDA Process Goals Electronic Labeling Rule Physician Labeling Rule Drug Listing Rule Manufacturer Repacker and Relabeler When to use medication How to use medication Description of Medication How supplied Distributor and manufacturer Indication, classifications, MOA, Interactions, AE Dose UNII, Ingredient names, Strength, Appearance, Dosage Form Name, Package type, Quantity Company ELIPS eLIST Approve Labeling QA/QC and Code Accessible medication information Accurate Identification of drugs and biologics on the market Populate Health Information Suppliers Decision Support Systems Populate NLM DailyMed Standardized FDA SPL

24 LISTING PROCESS Labeling Reviewers -CBER -CDER (OND, OGC, OC) FURLS/ Registration Health Care Community/ Public NLM -SPL -XML -CDRH Sponsors Manufacturers Repackers Relabelers eLIST/Listing -SPL -XML -NDC Directory ELIPS/ Labeling -CVM Listing Reviewers OC/DRLS Team Accept Input Data Validate NDC Validate/ Approve Listing Update Listing and Semi-Annual Certification Application Drugs w/ SPL Non-Application Drugs w/ SPL Drugs w/o SPL Drugs w/ Listed Source

25 Scope of Meeting – NDC Issues NDC number printed on product label Appropriate NDC number (of last firm handling product) Format of printed NDC number (NDC XXXXX-YYYY-ZZ) FDA assigns/issues the full NDC number NDC number & use restrictions Product code must be different for different formulation or manufacturer Must be the same for same formulation & manufacturer May not use same NDC number for different products May not use NDC for non-drugs NDC chain exempted from public disclosure Configuration of NDC number (10 vs 11 digits)